Brief: Enrollment Begins In Foresee Clinical Trial Using Biocept’S Cnside™ To Evaluate Patients With Leptomeningeal Metastases
24/03/2023 12:42
March 24 (Reuters) - Biocept Inc BIOC.O :
* ENROLLMENT BEGINS IN FORESEE CLINICAL TRIAL USING
BIOCEPT’S
CNSIDE™ TO EVALUATE PATIENTS WITH LEPTOMENINGEAL METASTASES
Source text for Eikon: ID:nBw5P8QNJa
Further company coverage: BIOC.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Biocept
See all newsBrief: Biocept Says Trading Of Common Stock Will Be Suspended By Nasdaq At Opening Of Business On Oct 25
U.S. STOCKS ON THE MOVE-Overstock.com, Biocept, Birkenstock
Biocept slumps after filing for bankruptcy protection
Brief: Biocept CEO Antonino Morales Resigns
U.S. STOCKS ON THE MOVE-Albemarle, Novavax, WeWork